Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017-18.

Findlay J, Gould VC, North P, Bowker KE, Williams MO, MacGowan AP, Avison MB.

J Antimicrob Chemother. 2019 Sep 20. pii: dkz397. doi: 10.1093/jac/dkz397. [Epub ahead of print]

PMID:
31538190
2.

Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.

Noel AR, Attwood M, Bowker KE, Kim A, Krause KM, MacGowan AP.

Int J Antimicrob Agents. 2019 Nov;54(5):626-632. doi: 10.1016/j.ijantimicag.2019.07.001. Epub 2019 Jul 9.

PMID:
31299297
3.

Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures.

Noel AR, Bowker KE, Attwood M, MacGowan AP.

J Antimicrob Chemother. 2019 Jul 1;74(7):1945-1951. doi: 10.1093/jac/dkz114.

PMID:
31220257
4.

An in vitro biofilm model of Staphylococcus aureus infection of bone.

Sweeney E, Lovering AM, Bowker KE, MacGowan AP, Nelson SM.

Lett Appl Microbiol. 2019 Apr;68(4):294-302. doi: 10.1111/lam.13131. Epub 2019 Mar 13.

PMID:
30770577
5.

Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.

Noel AR, Bowker KE, Attwood M, MacGowan AP.

J Antimicrob Chemother. 2018 Sep 1;73(9):2411-2417. doi: 10.1093/jac/dky225.

PMID:
30020472
6.

Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, Tomaselli S, Attwood M, MacGowan AP.

J Antimicrob Chemother. 2018 May 1;73(5):1305-1313. doi: 10.1093/jac/dky002.

PMID:
29562340
7.

Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection.

Alfouzan WA, Noel AR, Bowker KE, Attwood MLG, Tomaselli SG, MacGowan AP.

Int J Antimicrob Agents. 2017 Dec;50(6):715-717. doi: 10.1016/j.ijantimicag.2017.06.026. Epub 2017 Jul 10.

PMID:
28705678
8.

Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, Tomaselli S, MacGowan AP.

J Antimicrob Chemother. 2016 May;71(5):1270-8. doi: 10.1093/jac/dkv480. Epub 2016 Feb 3.

PMID:
26846209
9.

Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.

MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):515-21. doi: 10.1128/AAC.00727-15. Print 2016 Jan.

10.

Prevalence of antibiotic resistance in Escherichia coli isolated from urine samples routinely referred by general practitioners in a large urban centre in south-west England.

Chin TL, MacGowan AP, Bowker KE, Elder F, Beck CR, McNulty C.

J Antimicrob Chemother. 2015 Jul;70(7):2167-9. doi: 10.1093/jac/dkv050. Epub 2015 Mar 11. No abstract available.

PMID:
25766735
11.

Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Bowker KE.

Antimicrob Agents Chemother. 2013 Jun;57(6):2451-6. doi: 10.1128/AAC.01386-12. Epub 2013 Mar 4.

12.

Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum.

Bowker KE, Garvey MI, Noel AR, Tomaselli SG, Macgowan AP.

J Antimicrob Chemother. 2013 May;68(5):1130-8. doi: 10.1093/jac/dks537. Epub 2013 Jan 29.

PMID:
23361641
13.

Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.

Bowker KE, Noel AR, Tomaselli SG, Elliott H, Macgowan AP.

Antimicrob Agents Chemother. 2012 Oct;56(10):5009-15. doi: 10.1128/AAC.06111-11. Epub 2012 Jun 19.

14.

Reducing the risk of surgical site infection: a case controlled study of contamination of theatre clothing.

Sivanandan I, Bowker KE, Bannister GC, Soar J.

J Perioper Pract. 2011 Feb;21(2):69-72.

PMID:
21476422
15.

Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.

Antimicrob Agents Chemother. 2011 Feb;55(2):867-73. doi: 10.1128/AAC.00933-10. Epub 2010 Nov 15.

16.

Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.

MacGowan AP, Reynolds R, Noel AR, Bowker KE.

Antimicrob Agents Chemother. 2009 Dec;53(12):5181-4. doi: 10.1128/AAC.00118-09. Epub 2009 Oct 5.

17.

Headwear in laminar flow operating theatres.

Gordon RJ, Bannister GC, Bowker KE, Mason AC, Cheung LL, Eames R.

J Hosp Infect. 2009 Nov;73(3):289-91. doi: 10.1016/j.jhin.2009.08.001. Epub 2009 Sep 26. No abstract available.

PMID:
19783069
18.

Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, MacGowan AP.

J Antimicrob Chemother. 2009 Nov;64(5):1044-51. doi: 10.1093/jac/dkp289. Epub 2009 Sep 16.

PMID:
19759041
19.

In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.

Bowker KE, Caspers P, Gaucher B, MacGowan AP.

Antimicrob Agents Chemother. 2009 Nov;53(11):4949-52. doi: 10.1128/AAC.00845-09. Epub 2009 Sep 8.

20.

Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.

Bowker KE, Noel AR, Macgowan AP.

Antimicrob Agents Chemother. 2008 Dec;52(12):4370-3. doi: 10.1128/AAC.00922-07. Epub 2008 Jun 2.

21.
22.

Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory.

Soltani M, Tobin CM, Bowker KE, Sunderland J, MacGowan AP, Lovering AM.

Int J Antimicrob Agents. 2006 Dec;28(6):574-7. Epub 2006 Nov 7.

PMID:
17085019
23.

Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system.

Bowker KE, Noel AR, MacGowan AP.

J Antimicrob Chemother. 2006 Oct;58(4):802-5. Epub 2006 Aug 5.

PMID:
16891629
24.

Should finger rings be removed prior to scrubbing for theatre?

Kelsall NK, Griggs RK, Bowker KE, Bannister GC.

J Hosp Infect. 2006 Apr;62(4):450-2. Epub 2006 Feb 17.

PMID:
16487627
25.

Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.

Noel AR, Bowker KE, Macgowan AP.

Antimicrob Agents Chemother. 2005 Oct;49(10):4234-9.

26.

Discrepancy between viable counts and light output as viability measurements, following ciprofloxacin challenge of self-bioluminescent Pseudomonas aeruginosa biofilms.

Marques CN, Salisbury VC, Greenman J, Bowker KE, Nelson SM.

J Antimicrob Chemother. 2005 Oct;56(4):665-71. Epub 2005 Aug 16.

PMID:
16105852
27.

Topical fusidic acid/betamethasone-containing gel compared to systemic therapy in the treatment of canine acute moist dermatitis.

Cobb MA, Edwards HJ, Jagger TD, Marshall J, Bowker KE.

Vet J. 2005 Mar;169(2):276-80.

PMID:
15727921
28.
30.

In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens.

Bowker KE, Noel AR, MacGowan AP.

Int J Antimicrob Agents. 2003 Dec;22(6):557-61.

PMID:
14659651
31.

Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid.

Howe RA, Wootton M, Noel AR, Bowker KE, Walsh TR, MacGowan AP.

Antimicrob Agents Chemother. 2003 Nov;47(11):3651-2.

33.
34.

Effect of jewellery on surface bacterial counts of operating theatres.

Bartlett GE, Pollard TC, Bowker KE, Bannister GC.

J Hosp Infect. 2002 Sep;52(1):68-70.

PMID:
12372329
35.

Direct measurement of bacterial penetration through surgical gowns: a new method.

Lankester BJ, Bartlett GE, Garneti N, Blom AW, Bowker KE, Bannister GC.

J Hosp Infect. 2002 Apr;50(4):281-5.

PMID:
12014901
36.

In vitro activity of linezolid against Gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis patients.

Bowker KE, Wootton M, Holt HA, MacGowan AP.

J Antimicrob Chemother. 2002 Mar;49(3):578-80. No abstract available.

PMID:
11864965
37.
38.
39.

In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics.

Rynn C, Wootton M, Bowker KE, Alan Holt H, Reeves DS.

Clin Microbiol Infect. 1999 Jan;5(1):32-36.

40.

To disinfect or not to disinfect the foot in total joint arthroplasty of the lower limb.

Blom AW, Lankaster B, Bowker KE, Bannis GC.

J Hosp Infect. 2001 Dec;49(4):304-5. No abstract available.

PMID:
11740888
41.

The activity of vancomycin against heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus explored using an in vitro pharmacokinetic model.

Turner J, Howe RA, Wootton M, Bowker KE, Holt HA, Salisbury V, Bennett PM, Walsh TR, MacGowan AP.

J Antimicrob Chemother. 2001 Nov;48(5):727-30.

PMID:
11679564
42.

Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.

MacGowan AP, Rogers CA, Holt HA, Wootton M, Bowker KE.

Antimicrob Agents Chemother. 2001 Oct;45(10):2916-21.

43.

Use of meropenem 3 g once daily for outpatient treatment of infective exacerbations of bronchiectasis.

Darley ES, Bowker KE, Lovering AM, Harvey JE, Macgowan AP.

J Antimicrob Chemother. 2000 Feb;45(2):247-50.

PMID:
10660511
44.

Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin.

Bowker KE, Wootton M, Rogers CA, Lewis R, Holt HA, MacGowan AP.

J Antimicrob Chemother. 1999 Nov;44(5):661-7.

PMID:
10552983
45.
46.

In-vitro activity of HMR 3647 against Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and beta-haemolytic streptococci.

Wootton M, Bowker KE, Janowska A, Holt HA, MacGowan AP.

J Antimicrob Chemother. 1999 Oct;44(4):445-53.

PMID:
10588304
47.

A new method of assessing the penetration of bacteria through fabrics used in the operating theatre.

Blom AW, Estela CM, Bowker KE, MacGowan AP, Hardy JR.

J Hosp Infect. 1999 Sep;43(1):69-70. No abstract available.

PMID:
10462642
48.

Use of a clinical Escherichia coli isolate expressing lux genes to study the antimicrobial pharmacodynamics of moxifloxacin.

Salisbury V, Pfoestl A, Wiesinger-Mayr H, Lewis R, Bowker KE, MacGowan AP.

J Antimicrob Chemother. 1999 Jun;43(6):829-32.

PMID:
10404323
49.
50.

Surveillance of antimicrobial resistance.

MacGowan AP, Bowker KE, Bennett PM, Lovering AM.

Lancet. 1998 Nov 28;352(9142):1783. No abstract available.

PMID:
9848378

Supplemental Content

Loading ...
Support Center